Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Nanoligent

Nanoligent is a developer of nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer
2017
02-Oct
02-10
Barcelona, Spain
  • Drug Delivery and Devices
  • Drug Discovery and Development
  • Oncology (Cancer)
  • Personalized Medicine Technologies

Innovation

Industry Problem

Systemic cancer therapies can damage healthy tissue and may not deliver enough active drug to metastatic tumors.

R&D Focus

Protein-engineered targeted nanoparticles and precision oncology.

Innovative Solution

Designs multivalent protein nanoparticles that recognize tumor markers and deliver therapeutic payloads selectively.

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

$3.92M

Last Funding Amount

$3.05 M

Last Funding Date

9/27/2022

Startup Stage

Early Stage

Lead Investors

Archimedes Accelerator, i&i Biotech Fund, Landmark Capital (Italy), Avanteca Partners, B-Engine

People

Founders

CEO

About

Nanoligent is a developer of nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer

Products

Product

NNL1524, a CXCR4-targeted nanomedicine candidate.

Star Product

NNL1524, because it is the lead program advancing the targeted nanomedicine platform.

Demo Product or Complete Product?

Preclinical development stage with a lead oncology candidate.

Future Plan

Investment Funding

Closed a €12 million Series A in 2025; an earlier €1 million seed round was announced in 2022.

M&A and Collabs

Collab

Academic oncology and nanomedicine partners: preclinical validation.

Collab

European public research programs: development and translational support.

Something missing or incorrect on this page? Help us enrich this information